Literature DB >> 17668567

Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus.

Rita Medeiros1, Marie-Anne Rameix-Welti, Valérie Lorin, Patricia Ribaud, Jean-Claude Manuguerra, Gérard Socie, Catherine Scieux, Nadia Naffakh, Sylvie van der Werf.   

Abstract

Influenza A viruses are responsible for significant morbidity and mortality after bone marrow transplantation. Here we report failure of inhaled zanamivir treatment in a bone-marrow transplant recipient with pneumonia caused by an influenza A (H1N1) virus, although the influenza viruses isolated from bronchoalveolar lavages before and after treatment were clearly found to be sensitive to zanamivir using cell-based and enzymatic assays. Subsequent oral treatment with oseltamivir allowed complete recovery. Poor bioavailability of zanamivir in the peripheral lungs might have been limiting treatment efficacy in such an immunocompromised patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17668567

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  13 in total

1.  In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Authors:  Katrina Sleeman; Vasiliy P Mishin; Varough M Deyde; Yousuke Furuta; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

2.  Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.

Authors:  Shigeru Kohno; Muh-Yong Yen; Hee-Jin Cheong; Nobuo Hirotsu; Tadashi Ishida; Jun-ichi Kadota; Masashi Mizuguchi; Hiroshi Kida; Jingoro Shimada
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

3.  [Influenza : clinical symptoms, diagnostics and therapy].

Authors:  G G U Rohde
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

4.  Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.

Authors:  Shigeru Kohno; Hiroshi Kida; Masashi Mizuguchi; Nobuo Hirotsu; Tadashi Ishida; Junichi Kadota; Jingoro Shimada
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

5.  Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.

Authors:  Shigeru Kohno; Hiroshi Kida; Masashi Mizuguchi; Jingoro Shimada
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

Review 6.  Influenza prevention and treatment in transplant recipients and immunocompromised hosts.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

7.  Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.

Authors:  Mariana Baz; Yacine Abed; Benjamin Nehmé; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

Review 8.  Respiratory viral infections in transplant and oncology patients.

Authors:  Deepali Kumar; Atul Humar
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

9.  Mutations in H5N1 influenza virus hemagglutinin that confer binding to human tracheal airway epithelium.

Authors:  Guadalupe Ayora-Talavera; Holly Shelton; Margaret A Scull; Junyuan Ren; Ian M Jones; Raymond J Pickles; Wendy S Barclay
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

Review 10.  Current and future antiviral therapy of severe seasonal and avian influenza.

Authors:  John Beigel; Mike Bray
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.